GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Rituximab

Company
National Human Genome Research Institute (NHGRI)
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
68 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

68 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Rituximab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT00692939

    Autologous Stem Cell Transplantation for Crohn's Disease

    Not yet reported, Not yet reported Paul Szabolcs 20 participants Est. completion 2027-12 2 sites Stand-alone
    Other conditions: Crohn's Disease
    View official trial listing →
  • Recruiting NCT NCT02714634

    Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

    Not yet reported University Hospital, Strasbourg, France 286 participants Est. completion 2029-03 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
    View official trial listing →
  • Recruiting NCT NCT02836158

    Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

    Not yet reported, Not yet reported Navy General Hospital, Beijing 100 participants Est. completion 2030-12 1 site Stand-alone
    Other conditions: Primary Central Nervous System Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03136146

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

    Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2027-08-01 1 site Stand-alone
    Other conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03630211

    Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

    Not yet reported Paul Szabolcs 8 participants Est. completion 2028-08-01 3 sites Stand-alone
    Other conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
    View official trial listing →
  • Recruiting NCT NCT03952637

    A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

    Not yet reported, Not yet reported National Human Genome Research Institute (NHGRI) 54 participants Est. completion 2030-01-01 1 site Stand-alone
    Other conditions: Lysosomal Diseases, Gangliosidosis, GM1
    View official trial listing →
  • Recruiting NCT NCT03980002

    A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 50 participants Est. completion 2027-12-30 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT04022239

    Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 25 participants Est. completion 2027-07-31 1 site Stand-alone
    Other conditions: Hematopoietic and Lymphoid System Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04656431

    Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

    Not yet reported James Rubenstein 26 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Primary CNS Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04669171

    A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported Enterome 80 participants Est. completion 2034-05-30 12 sites Stand-alone
    Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04737889

    Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

    Not yet reported Henan Cancer Hospital 30 participants Est. completion 2026-01-13 1 site Stand-alone
    Other conditions: Primary Central Nervous System Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04998669

    Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Juan P. Alderuccio, MD 100 participants Est. completion 2030-08-01 5 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05136976

    Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

    Not yet reported Centre Hospitalier Universitaire de Saint Etienne 90 participants Est. completion 2028-12 15 sites
    Other conditions: Anti-MAG Neuropathy
    View official trial listing →
  • Recruiting NCT NCT05245656

    A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

    Not yet reported Kim, Seok Jin 90 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05508009

    Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

    Not yet reported, Not yet reported Alice Bertaina 12 participants Est. completion 2034-10 1 site Stand-alone
    Chronic kidney disease Other conditions: SIOD, Cystinosis, FSGS, SLE Nephritis
    View official trial listing →
  • Recruiting NCT NCT05581030

    CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 7 participants Est. completion 2026-10 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05600686

    Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

    Not yet reported University of California, Davis 24 participants Est. completion 2027-12-15 2 sites Stand-alone
    Other conditions: Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
    View official trial listing →
  • Recruiting NCT NCT05758831

    RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

    Not yet reported Rennes University Hospital 386 participants Est. completion 2030-05-01 23 sites Stand-alone
    Other conditions: Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT05783609

    Epcoritamab and Rituximab for First-line Follicular Lymphoma

    Not yet reported Reid Merryman, MD 100 participants Est. completion 2030-02 6 sites Stand-alone
    Other conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
    View official trial listing →
  • Recruiting NCT NCT05786040

    Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

    Not yet reported Timothy Voorhees 28 participants Est. completion 2027-12-31 4 sites Stand-alone
    Other conditions: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
    View official trial listing →
  • Recruiting NCT NCT05962177

    Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

    Not yet reported University Hospital, Montpellier 400 participants Est. completion 2030-06 1 site Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT05992597

    ZR2 Sequential Immunochemotherapy for Newly Treated MCL

    Not yet reported Zhejiang Cancer Hospital 48 participants Est. completion 2026-12-01 1 site Stand-alone
    Other conditions: Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06003283

    Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

    Not yet reported Universitaire Ziekenhuizen KU Leuven 134 participants Est. completion 2027-12 7 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT06082102

    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

    Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 324 participants Est. completion 2030-02-25 19 sites Stand-alone
    Other conditions: Relapsed/Refractory Marginal Zone Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06084936

    A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported Hoffmann-La Roche 182 participants Est. completion 2028-03-31 82 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06263491

    Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2027-03-01 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06284122

    Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

    Not yet reported The Lymphoma Academic Research Organisation 790 participants Est. completion 2034-04 116 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06337318

    Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    Not yet reported National Cancer Institute (NCI) 600 participants Est. completion 2032-03-31 276 sites Stand-alone
    Other conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
    View official trial listing →
  • Recruiting NCT NCT06350318

    Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 43 participants Est. completion 2029-03 1 site Stand-alone
    Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06364423

    Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

    Not yet reported, Not yet reported National Cancer Institute (NCI) 132 participants Est. completion 2030-07-01 1 site Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Leukemia, Acute Lymphoblastic, Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06482684

    CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

    Not yet reported Christian Schmidt, MD 150 participants Est. completion 2031-12-31 2 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06489808

    Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 89 participants Est. completion 2027-05-31 1 site Stand-alone
    Other conditions: Relapsed/Refractory Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06496308

    Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

    Not yet reported Ruijin Hospital 78 participants Est. completion 2027-07-10 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma (MCL)
    View official trial listing →
  • Recruiting NCT NCT06522555

    The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

    Not yet reported Ruijin Hospital 100 participants Est. completion 2029-08-10 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06564038

    A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

    Not yet reported, Not yet reported AstraZeneca 408 participants Est. completion 2029-06-11 65 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06594640

    R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 108 participants Est. completion 2027-07-30 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06611696

    Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis

    Not yet reported Chiba University 160 participants Est. completion 2028-09-30 22 sites Stand-alone
    Other conditions: ANCA Associated Vasculitis (AAV)
    View official trial listing →
  • Recruiting NCT NCT06647732

    Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

    Not yet reported Sun Yat-sen University 42 participants Est. completion 2028-09-30 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Recruiting NCT NCT06663111

    Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

    Haukeland University Hospital 60 participants Est. completion 2027-12-31 1 site
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT06688331

    Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

    Not yet reported PolTREG S.A. 150 participants Est. completion 2032-12 9 sites Stand-alone
    Other conditions: Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
    View official trial listing →
  • Recruiting NCT NCT06701357

    CR-CHOP+X in Previously Untreated DEL

    Not yet reported Ruijin Hospital 49 participants Est. completion 2028-12-01 1 site Stand-alone
    Other conditions: DLBCL
    View official trial listing →
  • Recruiting NCT NCT06714838

    Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

    Not yet reported Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC) 100 participants Est. completion 2028-10 1 site Stand-alone
    Other conditions: CIDP
    View official trial listing →
  • Recruiting NCT NCT06737250

    NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

    Not yet reported NOBO Medicine 33 participants Est. completion 2027-12-31 10 sites Stand-alone
    Other conditions: Primary CNS Lymphoma (PCNSL)
    View official trial listing →
  • Recruiting NCT NCT06738368

    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

    Not yet reported University of Washington 30 participants Est. completion 2028-07-30 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06743945

    POLA-R-CHP in the First-line Treatment of Transformed DLBCL

    Not yet reported Fudan University 20 participants Est. completion 2029-12 1 site Stand-alone
    Other conditions: Transformed Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06788964

    Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

    Not yet reported University of Utah 29 participants Est. completion 2030-03 1 site Stand-alone
    Other conditions: Relapsed or Refractory Large B-cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06803693

    Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

    Not yet reported Ruijin Hospital 152 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06830421

    Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

    Not yet reported University Hospital Freiburg 340 participants Est. completion 2031-08-31 35 sites Stand-alone
    Other conditions: Primary Central Nervous System Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06832267

    Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

    Not yet reported Zhejiang Cancer Hospital 44 participants Est. completion 2028-02-13 1 site Stand-alone
    Other conditions: Primary Central Nervous System Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06854003

    BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

    Not yet reported Christine Ryan 60 participants Est. completion 2039-11-01 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma, Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06905509

    Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

    Not yet reported University of California, Davis 25 participants Est. completion 2030-08-01 1 site Stand-alone
    Other conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Nodal Marginal Zone Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06946407

    Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma

    Not yet reported FengYan Jin 41 participants Est. completion 2029-12-01 1 site Stand-alone
    Other conditions: Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment
    View official trial listing →
  • Recruiting NCT NCT06980584

    Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension

    Not yet reported Beijing Chao Yang Hospital 48 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Fibrosing Mediastinitis, Pulmonary Hypertension
    View official trial listing →
  • Recruiting NCT NCT06983821

    Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)

    Not yet reported Ottawa Hospital Research Institute 36 participants Est. completion 2029-02 2 sites Stand-alone
    Other conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)
    View official trial listing →
  • Recruiting NCT NCT07002099

    Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

    Not yet reported Second Affiliated Hospital of Soochow University 26 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Lymphomas
    View official trial listing →
  • Recruiting NCT NCT07104032

    IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

    Not yet reported Ono Pharmaceutical Co., Ltd. 132 participants Est. completion 2029-12 33 sites
    Other conditions: Relapsed/Refractory Primary Central Nervous System Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07139873

    A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

    Not yet reported Dizal Pharmaceuticals 250 participants Est. completion 2029-12 2 sites
    Other conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07231952

    A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

    Not yet reported Memorial Sloan Kettering Cancer Center 40 participants Est. completion 2028-04-11 9 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07350850

    A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL

    Not yet reported Tongji Hospital 77 participants Est. completion 2029-06-30 4 sites Stand-alone
    Other conditions: PCNSL, Primary Central Nervous System Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07355699

    Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

    Not yet reported Beijing Tongren Hospital 88 participants Est. completion 2028-12-31 3 sites Stand-alone
    Other conditions: Marginal Zone Lymphoma(MZL)
    View official trial listing →
  • Recruiting NCT NCT07362238

    Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 122 participants Est. completion 2028-03 1 site
    Other conditions: Immune Thrombocytopenia, Treatment
    View official trial listing →
  • Recruiting NCT NCT07448324

    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 50 participants Est. completion 2030-01-01 1 site Stand-alone
    Other conditions: Marginal Zone Lymphoma(MZL)
    View official trial listing →
  • Recruiting NCT NCT07493148

    Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

    Not yet reported Ou Bai, MD/PHD 50 participants Est. completion 2029-12-30 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
    View official trial listing →
  • Recruiting NCT NCT07509840

    Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency

    Not yet reported Angelica Lindén Hirschberg 40 participants Est. completion 2031-12-31 2 sites
    Other conditions: Autoimmune Prematur Ovarian Insuffience
    View official trial listing →
  • Recruiting NCT NCT07604987

    R-PMDT Regimen in Newly Diagnosed PCNSL

    Not yet reported Zou Dehui 33 participants Est. completion 2030-05-20 1 site Stand-alone
    Other conditions: Primary Central Nervous System (CNS) Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07608978

    Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 35 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
    View official trial listing →
  • Recruiting NCT NCT07693881

    Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

    Not yet reported Nanfang Hospital, Southern Medical University 106 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: EBV Infection After Allogenic HSCT
    View official trial listing →
  • Recruiting NCT NCT07775235

    Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease

    Singapore General Hospital 80 participants Est. completion 2029-07-01 1 site
    Other conditions: Interstitial Lung Disease, Myositis
    View official trial listing →
  • Completed NCT NCT00001563

    EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

    Not yet reported National Cancer Institute (NCI) 39 participants Est. completion 2005-05-05 1 site Stand-alone
    Other conditions: AIDS Related Lymphoma, AIDS-Associated Lymphoma
    View official trial listing →
  • Completed NCT NCT00003280

    Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma

    Not yet reported Swiss Cancer Institute 240 participants Est. completion 2002-03 10 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00003554

    Rituximab in Treating Patients With Multiple Myeloma

    Not yet reported The Cleveland Clinic Est. completion 2004-04 1 site
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00003658

    Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

    Not yet reported Memorial Sloan Kettering Cancer Center 60 participants Est. completion 2005-10 1 site
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00004179

    Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 475 participants Est. completion 2017-07-19 261 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00005652

    Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

    Not yet reported University of Alabama at Birmingham 20 participants 1 site
    Other conditions: Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00005780

    Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 26 participants Est. completion 2021-06-16 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma, Lymphoma, Mantle Cell
    View official trial listing →
  • Completed NCT NCT00006436

    EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

    Not yet reported National Cancer Institute (NCI) 68 participants Est. completion 2024-01-18 1 site Stand-alone
    Other conditions: Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Completed NCT NCT00020943

    Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 79 participants Est. completion 2009-09 81 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00026182

    Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

    Not yet reported National Cancer Institute (NCI) 99 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
    View official trial listing →
  • Terminated NCT NCT00036855

    Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

    Not yet reported National Cancer Institute (NCI) 36 participants 1 site Stand-alone
    Other conditions: AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT00057447

    Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

    Not yet reported, Not yet reported InterMune 24 participants Est. completion 2004-06 1 site
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00062296

    Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

    Not yet reported Fox Chase Cancer Center 5 participants Est. completion 2005-08 1 site
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00064116

    Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma

    Not yet reported NCIC Clinical Trials Group 824 participants Est. completion 2014-01-16 25 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00066469

    Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

    Not yet reported Children's Oncology Group 55 participants Est. completion 2013-12-31 78 sites Stand-alone
    Other conditions: Lymphoproliferative Disorder
    View official trial listing →
  • Completed NCT NCT00070083

    Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

    Not yet reported British Columbia Cancer Agency 4 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00074165

    Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

    Not yet reported OHSU Knight Cancer Institute 17 participants Est. completion 2010-12 2 sites Stand-alone
    Other conditions: Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00086775

    Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

    Not yet reported Bayer Est. completion 2009-10 5 sites
    Other conditions: Leukemia
    View official trial listing →
  • Terminated NCT NCT00087009

    Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

    Not yet reported Memorial Sloan Kettering Cancer Center 3 participants Est. completion 2008-08 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma, Lymphoproliferative Disorder
    View official trial listing →
  • Active, not recruiting NCT NCT00092222

    Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

    Not yet reported National Cancer Institute (NCI) 75 participants Est. completion 2026-10-01 1 site
    Other conditions: Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
    View official trial listing →
  • Completed NCT NCT00098774

    Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 47 participants Est. completion 2014-09 30 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00101010

    Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 80 participants Est. completion 2014-09 7 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00107614

    DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients

    Not yet reported University of Arkansas 12 participants Est. completion 2008-02 1 site Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00129090

    Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma

    Not yet reported German High-Grade Non-Hodgkin's Lymphoma Study Group 450 participants Est. completion 2017-10 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma (NHL)
    View official trial listing →
  • Completed NCT NCT00133991

    Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23 participants Est. completion 2013-08 2 sites Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00140582

    Primary Rituximab and Maintenance

    Not yet reported Lymphoma Study Association 1217 participants Est. completion 2016-12 24 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT00141700

    Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

    Not yet reported University of Michigan Rogel Cancer Center 30 participants Est. completion 2005-12 1 site
    Other conditions: Lymphoma, Non-Hodgkin's
    View official trial listing →
  • Terminated NCT NCT00142168

    CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

    Not yet reported Dana-Farber Cancer Institute 16 participants Est. completion 2008-04 2 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00143559

    Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies

    Not yet reported St. Jude Children's Research Hospital 17 participants Est. completion 2009-01 1 site
    Other conditions: Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00166439

    Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

    Not yet reported Academic and Community Cancer Research United 50 participants Est. completion 2015-09 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00169156

    A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

    Not yet reported Lymphoma Study Association 27 participants Est. completion 2012-11 4 sites Stand-alone
    Other conditions: Untreated T-cell Angioimmunoblastic Lymphoma
    View official trial listing →
  • Completed NCT NCT00169195

    Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

    Not yet reported Lymphoma Study Association 49 participants Est. completion 2012-11 8 sites Stand-alone
    Other conditions: Diffuse Large Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00169468

    Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

    Not yet reported Lymphoma Study Association 48 participants Est. completion 2006-01 4 sites
    Other conditions: B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00186823

    Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies

    Not yet reported St. Jude Children's Research Hospital 57 participants Est. completion 2009-01 1 site
    Other conditions: Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia(JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
    View official trial listing →
  • Completed NCT NCT00199082

    Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

    Not yet reported Nicola Goekbuget 650 participants Est. completion 2010-06 1 site Stand-alone
    Other conditions: Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Neoplasms, Lymphoblastic Lymphoma, Large Cell Anaplastic Lymphoma
    View official trial listing →
  • Terminated NCT NCT00202930

    Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

    Not yet reported Jean M. Tersak, M.D. 4 participants Est. completion 2009-02-05
    Other conditions: Neuroblastoma, Opsoclonus-myoclonus
    View official trial listing →
  • Completed NCT NCT00204659

    Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    Not yet reported University Hospital Tuebingen 30 participants Est. completion 2008-09 5 sites
    Other conditions: Primary Gastric Diffuse-Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00210379

    Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 64 participants Est. completion 2007-03 1 site
    Other conditions: Lymphoma, B Cell
    View official trial listing →
  • Completed NCT NCT00238238

    Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

    Not yet reported Alliance for Clinical Trials in Oncology 97 participants Est. completion 2015-08 79 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00244127

    Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

    Not yet reported Zeneus Pharma 75 participants 5 sites
    Other conditions: Aggressive Non-Hodgkin's Lymphoma in the Elderly.
    View official trial listing →
  • Completed NCT NCT00244855

    Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

    Not yet reported Fred Hutchinson Cancer Center 32 participants Est. completion 2011-08-29 1 site
    Obstructive sleep apnea Other conditions: Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Marginal Zone Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00254410

    FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2017-09-14 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00255593

    Safety and Efficacy Study of Rituximab in Renal Transplantation

    Not yet reported Karolinska University Hospital 140 participants Est. completion 2007-10 1 site
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00258206

    Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 21 participants Est. completion 2007-09-07 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Terminated NCT NCT00265928

    Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Not yet reported University of Virginia 46 participants 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00267826

    Immunopharmacological Effects of Rituximab in Atopic Dermatitis

    Not yet reported University of Bern 6 participants Est. completion 2006-12 1 site Stand-alone
    Other conditions: Dermatitis, Atopic
    View official trial listing →
  • Completed NCT NCT00267865

    Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

    Not yet reported National Cancer Institute (NCI) 12 participants Est. completion 2019-09-19 1 site Stand-alone
    Other conditions: AIDS-Related-Primary Central Nervous System Lymphoma
    View official trial listing →
  • Completed NCT NCT00268853

    A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin

    Not yet reported CTI BioPharma 124 participants Est. completion 2012-05 75 sites Stand-alone
    Other conditions: Diffuse Large-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00282308

    A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

    Not yet reported Genentech, Inc. 103 participants Est. completion 2012-05-28 34 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT00286780

    Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

    Not yet reported Ascenta Therapeutics 19 participants Est. completion 2007-11 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00293072

    Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 20 participants Est. completion 2005-05 1 site
    Other conditions: Systemic Lupus Erythematosus, ANCA Associated Vasculitis
    View official trial listing →
  • Completed NCT NCT00294632

    Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 54 participants Est. completion 2016-02 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00301821

    Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 107 participants Est. completion 2015-04 162 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00310128

    Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

    Not yet reported AIDS Malignancy Consortium
    Other conditions: AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00311129

    Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

    Not yet reported Genzyme, a Sanofi Company 41 participants Est. completion 2007-07 8 sites Stand-alone
    Other conditions: Lymphoma, Low-Grade
    View official trial listing →
  • Completed NCT NCT00324779

    Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

    Not yet reported University Hospital Erlangen 79 participants 38 sites
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00330252

    Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

    Not yet reported Dana-Farber Cancer Institute 29 participants Est. completion 2014-01 2 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00345865

    Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

    Not yet reported Masonic Cancer Center, University of Minnesota 473 participants Est. completion 2019-06-28 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00347971

    Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

    Not yet reported ZymoGenetics 23 participants Est. completion 2008-04 1 site
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Terminated NCT NCT00354822

    Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.

    Not yet reported A.O. Ospedale Papa Giovanni XXIII 25 participants Est. completion 2009-08 6 sites
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00366275

    Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 64 participants Est. completion 2007-09 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00369681

    Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 51 participants Est. completion 2014-10 4 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00371904

    Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients

    Not yet reported Hunter and New England Health 192 participants Est. completion 2009-01 3 sites Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00376961

    S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported SWOG Cancer Research Network 68 participants Est. completion 2017-09 147 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00381810

    A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

    Not yet reported Genentech, Inc. 31 participants Est. completion 2012-02-29 11 sites Stand-alone
    Other conditions: Lupus Erythematosus, Systemic
    View official trial listing →
  • Terminated NCT NCT00384111

    Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

    Not yet reported Spectrum Pharmaceuticals, Inc 26 participants Est. completion 2008-11 6 sites Stand-alone
    Other conditions: Follicular Lymphoma, Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT00392834

    Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

    Not yet reported AIDS Malignancy Consortium 34 participants Est. completion 2013-07 13 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00394836

    HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

    Not yet reported GlaxoSmithKline 116 participants Est. completion 2013-09 1 site
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT00415506

    Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

    Not yet reported, Not yet reported Oregon Health and Science University 20 participants Est. completion 2011-03 1 site Stand-alone
    Other conditions: Scleritis, Orbital Disease
    View official trial listing →
  • Completed NCT NCT00422799

    Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

    Not yet reported Dana-Farber Cancer Institute 63 participants Est. completion 2015-10-09 1 site Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00425217

    Rituximab in Membranous Nephropathy

    Not yet reported, Not yet reported Mayo Clinic 15 participants Est. completion 2007-04 1 site
    Other conditions: Membranous Nephropathy
    View official trial listing →
  • Completed NCT NCT00425802

    Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

    Not yet reported Memorial Sloan Kettering Cancer Center 61 participants Est. completion 2016-10-28 1 site
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00429065

    Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

    Instituto Nacional de Cancerologia de Mexico 30 participants Est. completion 2007-01 1 site
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00439556

    Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2018-06-07 1 site Stand-alone
    Other conditions: CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
    View official trial listing →
  • Completed NCT NCT00460109

    Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 24 participants Est. completion 2011-03 165 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00468442

    B-Lymphocyte Immunotherapy in Islet Transplantation

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 2 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT00486759

    A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

    Not yet reported Hoffmann-La Roche 787 participants Est. completion 2011-11-30 266 sites Stand-alone
    Other conditions: B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00500058

    A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

    Not yet reported GlaxoSmithKline 24 participants Est. completion 2010-03-04 2 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00501748

    Safety and Tolerability of Rituximab in Neuromyelitis Optica

    Not yet reported University of California, San Francisco 20 participants Est. completion 2010-12 2 sites Stand-alone
    Other conditions: Neuromyelitis Optica
    View official trial listing →
  • Completed NCT NCT00503425

    A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

    Not yet reported Hoffmann-La Roche 215 participants Est. completion 2013-05-26 16 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Withdrawn NCT NCT00504491

    R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia

    Not yet reported CABYC Est. completion 2012-06 32 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukaemia, Patients Resistant to a Purine Analogous, Patients Relapsed With Purines Therapy
    View official trial listing →
  • Completed NCT NCT00504777

    A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.

    Not yet reported Hoffmann-La Roche 36 participants Est. completion 2010-03 10 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT00510887

    Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

    Not yet reported Duke University 14 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT00514475

    Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

    Not yet reported Oslo University Hospital 160 participants Est. completion 2009-06 1 site
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00529503

    A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

    Not yet reported Seagen Inc. 151 participants Est. completion 2011-05 66 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00536341

    Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported SCRI Development Innovations, LLC 64 participants Est. completion 2016-11 6 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00537290

    A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

    Not yet reported Hospital for Special Surgery, New York 19 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Antiphospholipid Syndrome
    View official trial listing →
  • Completed NCT NCT00546377

    Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 50 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00547534

    Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

    Not yet reported University of Rochester 31 participants Est. completion 2009-10 3 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00558181

    High-dose Methylprednisolone and Rituximab in High Risk B-CLL

    Not yet reported Vilnius University 29 participants Est. completion 2009-12 2 sites Stand-alone
    Other conditions: Chronic B-Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00558220

    R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas

    Not yet reported Czech Lymphoma Study Group 106 participants Est. completion 2006-10 8 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma., Primary Mediastinal B-Cell Lymphoma, Follicular Lymphoma Grade III
    View official trial listing →
  • Completed NCT NCT00562328

    Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

    Not yet reported Mayo Clinic 33 participants Est. completion 2014-12-18 2 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00581854

    Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

    Not yet reported University of Wisconsin, Madison 22 participants Est. completion 2010-03 1 site
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00582816

    Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

    Not yet reported, Not yet reported University of Wisconsin, Madison 9 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Leukemia, Solid Tumors
    View official trial listing →
  • Completed NCT NCT00601718

    Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

    Not yet reported, Not yet reported University of Washington 29 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00633594

    Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

    Not yet reported, Not yet reported SCRI Development Innovations, LLC 39 participants Est. completion 2016-11 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00637832

    Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

    Not yet reported University of Southampton 1 participants Est. completion 2015-01-06 5 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00641095

    Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma

    Not yet reported, Not yet reported University College, London 370 participants Est. completion 2015-05-22 67 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00646750

    Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 31 participants Est. completion 2012-06 18 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00648037

    Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

    Not yet reported Memorial Sloan Kettering Cancer Center 26 participants Est. completion 2008-12 1 site Stand-alone
    Other conditions: Hodgkin's Disease, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00664599

    Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

    Not yet reported Tehran University of Medical Sciences 20 participants Est. completion 2008-01 1 site Stand-alone
    Other conditions: Behcet's Syndrome
    View official trial listing →
  • Completed NCT NCT00669318

    Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported Mayo Clinic 41 participants Est. completion 2014-05 3 sites Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00689169

    Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma

    Not yet reported Lymphoma Study Association 75 participants Est. completion 2014-01 1 site Stand-alone
    Other conditions: Lymphoma, Large Cell, Diffuse
    View official trial listing →
  • Completed NCT NCT00691015

    Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

    Not yet reported Barbara Ann Karmanos Cancer Institute 48 participants Est. completion 2014-04 1 site Stand-alone
    Other conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    View official trial listing →
  • Completed NCT NCT00697996

    Rituximab for Pediatric Renal Transplant Rejection

    Not yet reported, Not yet reported Stanford University 20 participants Est. completion 2007-08 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00701129

    An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

    Not yet reported Genzyme, a Sanofi Company 4 participants Est. completion 2013-03 2 sites Stand-alone
    Other conditions: Pompe Disease, Glycogen Storage Disease Type II
    View official trial listing →
  • Completed NCT NCT00719472

    A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)

    Not yet reported Genentech, Inc. 451 participants Est. completion 2011-05 Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00720135

    Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

    Not yet reported City of Hope Medical Center 9 participants Est. completion 2014-07 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Withdrawn NCT NCT00723658

    S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

    Not yet reported SWOG Cancer Research Network 29 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00749112

    Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

    Not yet reported, Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 19 participants Est. completion 2010-08 1 site Stand-alone
    Other conditions: Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune
    View official trial listing →
  • Terminated NCT NCT00772668

    Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

    Not yet reported University of Miami 3 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT00788684

    Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

    Not yet reported AbbVie 29 participants Est. completion 2025-02-07 6 sites Stand-alone
    Other conditions: CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00797810

    Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults

    Not yet reported University of Bologna 25 participants 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00799136

    A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL

    Not yet reported Ontario Clinical Oncology Group (OCOG) 6 participants Est. completion 2013-09 2 sites
    Other conditions: Lymphoma, AIDS Related, HIV Infections
    View official trial listing →
  • Completed NCT NCT00801281

    First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

    Not yet reported Polish Lymphoma Research Group 250 participants Est. completion 2017-06-25 12 sites Stand-alone
    Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00801580

    My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia

    Not yet reported University of Bologna 3 participants Est. completion 2010-09 1 site Stand-alone
    Other conditions: Lymphoid Leukemia
    View official trial listing →
  • Terminated NCT NCT00809341

    R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27 participants Est. completion 2014-04 1 site
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00829205

    Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

    Not yet reported, Not yet reported Cancer Research UK 5 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00859001

    Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy

    Not yet reported University of Bologna 55 participants 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT00869323

    Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

    Not yet reported Masonic Cancer Center, University of Minnesota 3 participants Est. completion 2016-12 2 sites Stand-alone
    Other conditions: Lymphoproliferative Disorder
    View official trial listing →
  • Completed NCT NCT00875667

    A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

    Not yet reported Celgene 254 participants Est. completion 2018-10-09 97 sites
    Other conditions: Mantle Cell Lymphoma, Lymphoma, Mantle-Cell
    View official trial listing →
  • Withdrawn NCT NCT00881387

    Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

    Not yet reported University of Miami Est. completion 2012-10 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00908986

    Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis

    Not yet reported Northwell Health Est. completion 2009-11 Stand-alone
    Other conditions: Lupus Nephritis
    View official trial listing →
  • Completed NCT NCT00918723

    Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 40 participants Est. completion 2016-10 2 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00927797

    Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)

    Not yet reported Heidelberg University 185 participants Est. completion 2012-01 Stand-alone
    Other conditions: Immunocytoma/Morbus Waldenström, B-Cell Non-Hodgkin's Lymphoma, B-Cell Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00936546

    A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

    Not yet reported University Hospital, Ghent 3 participants Est. completion 2015-06-03 1 site Stand-alone
    Other conditions: Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
    View official trial listing →
  • Completed NCT NCT00945724

    Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 54 participants Est. completion 2023-09-26 22 sites Stand-alone
    Other conditions: Large B-cell Diffuse Lymphoma of Testis
    View official trial listing →
  • Terminated NCT NCT00949988

    A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported University of California, San Diego 3 participants Est. completion 2012-04 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00968331

    Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

    Not yet reported University of Bologna 25 participants Est. completion 2011-12 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT00972478

    Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 83 participants Est. completion 2027-03-06 190 sites Stand-alone
    Other conditions: Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT00986947

    Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

    Not yet reported Johns Hopkins University 20 participants Est. completion 2011-07 1 site Stand-alone
    Other conditions: Kidney Failure
    View official trial listing →
  • Completed NCT NCT00991211

    Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

    Not yet reported University of Giessen 549 participants Est. completion 2009-08 1 site Stand-alone
    Other conditions: Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas, Marginal Zone Lymphomas
    View official trial listing →
  • Completed NCT NCT00996593

    Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

    Not yet reported GlaxoSmithKline 43 participants Est. completion 2009-08
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT01004991

    Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

    Not yet reported, Not yet reported Weill Medical College of Cornell University 14 participants Est. completion 2016-02 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01015248

    Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 60 participants Est. completion 2013-12 19 sites Stand-alone
    Other conditions: MALT LYMPHOMA
    View official trial listing →
  • Completed NCT NCT01021735

    Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

    Not yet reported University of Glasgow 302 participants Est. completion 2015-04 8 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01055496

    Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

    Not yet reported Pfizer 103 participants Est. completion 2014-03 28 sites Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT01085617

    Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

    University College, London Est. completion 2025-02-24 Stand-alone
    Other conditions: Leukemia, Mucositis, Oral Complications
    View official trial listing →
  • Completed NCT NCT01092182

    Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 194 participants Est. completion 2023-02-16 30 sites Stand-alone
    Other conditions: Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
    View official trial listing →
  • Terminated NCT NCT01103388

    Rituximab Maintenance After Autologous Transplantation

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2010-04 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT01117662

    Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients

    Not yet reported Hannover Medical School 13 participants Est. completion 2016-08-23 14 sites Stand-alone
    Other conditions: Acute Rejection
    View official trial listing →
  • Terminated NCT NCT01119794

    Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

    Not yet reported Brown University 10 participants Est. completion 2015-07 3 sites
    Other conditions: Lymphoma, Non-Hodgkins
    View official trial listing →
  • Completed NCT NCT01125176

    Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

    Not yet reported Weill Medical College of Cornell University 15 participants Est. completion 2020-12-29 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01161628

    Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)

    Not yet reported Northside Hospital, Inc. 25 participants Est. completion 2015-07 1 site Stand-alone
    Other conditions: Chronic Graft-versus-host Disease
    View official trial listing →
  • Terminated NCT NCT01164098

    Rituximab to Prevent Recurrence of Proteinuria

    Not yet reported George W. Burke 30 participants Est. completion 2016-10 1 site
    Other conditions: FSGS, Proteinuria
    View official trial listing →
  • Completed NCT NCT01178216

    Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

    Not yet reported, Not yet reported Stanley Jordan, MD 41 participants Est. completion 2017-07-28 1 site Stand-alone
    Other conditions: End Stage Renal Disease
    View official trial listing →
  • Completed NCT NCT01185262

    Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

    Not yet reported MD Anderson International Spain SA 25 participants Est. completion 2013-09 7 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT01196780

    An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)

    Hoffmann-La Roche 1240 participants Est. completion 2015-10 1 site
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT01196884

    Immune Thrombocytopenia (ITP) Immune-Genetic Assessment

    Azienda Sanitaria-Universitaria Integrata di Udine 190 participants 13 sites
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT01205737

    A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

    Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 186 participants Est. completion 2013-09 41 sites
    Other conditions: DLBCL
    View official trial listing →
  • Terminated NCT NCT01207765

    Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

    Not yet reported Tufts Medical Center 8 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01209130

    A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

    Not yet reported Genentech, Inc. 91 participants Est. completion 2015-03 9 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01216683

    Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

    Not yet reported ECOG-ACRIN Cancer Research Group 289 participants Est. completion 2019-12-02 227 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT01235793

    The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma

    Not yet reported Cedars-Sinai Medical Center 11 participants Est. completion 2018-04-18 1 site Stand-alone
    Other conditions: B-Cell Lymphoma Originating in the CNS
    View official trial listing →
  • Withdrawn NCT NCT01238146

    Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
    View official trial listing →
  • Terminated NCT NCT01253460

    Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2019-02-13 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT01267812

    Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

    Not yet reported City of Hope Medical Center 23 participants Est. completion 2020-11-02 2 sites Stand-alone
    Other conditions: Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01271010

    A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status

    Not yet reported Hoffmann-La Roche 89 participants Est. completion 2016-05-04 10 sites Stand-alone
    Other conditions: Lymphocytic Leukemia, Chronic
    View official trial listing →
  • Completed NCT NCT01274182

    GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

    Not yet reported, Not yet reported Sandoz 312 participants Est. completion 2016-11 57 sites
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT01279616

    A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

    Not yet reported Nationwide Children's Hospital 8 participants Est. completion 2015-01 1 site Stand-alone
    Other conditions: Sickle Cell Disease
    View official trial listing →
  • Completed NCT NCT01283399

    An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

    Hoffmann-La Roche 79 participants Est. completion 2014-04 5 sites
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01285765

    Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

    Not yet reported The Lymphoma Academic Research Organisation 650 participants Est. completion 2020-05-23 83 sites Stand-alone
    Other conditions: DLBCL
    View official trial listing →
  • Completed NCT NCT01290120

    Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma

    Not yet reported Northern Italy Leukemia Group 182 participants Est. completion 2014-06 12 sites
    Other conditions: Burkitt Lymphoma, B-ALL
    View official trial listing →
  • Completed NCT NCT01299857

    Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab

    Not yet reported University Hospital, Rouen 22 participants Est. completion 2012-06 1 site
    Other conditions: Pemphigus
    View official trial listing →
  • Completed NCT NCT01307267

    A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

    Not yet reported Pfizer 190 participants Est. completion 2019-02-20 42 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Malignant Melanoma
    View official trial listing →
  • Completed NCT NCT01311232

    Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab

    Samsung Medical Center 600 participants Est. completion 2013-12-01 4 sites
    Other conditions: Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
    View official trial listing →
  • Terminated NCT NCT01313611

    BRIEF Bendamustine and Rituximab In Elderly Follicular

    Not yet reported The Lymphoma Academic Research Organisation 62 participants Est. completion 2017-12 117 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT01317966

    Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

    Ming Hou Est. completion 2012-03 1 site
    Other conditions: Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Terminated NCT NCT01318915

    Research Study of ATG and Rituximab in Renal Transplantation

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 10 participants Est. completion 2017-08-25 6 sites Stand-alone
    Other conditions: Renal Transplant Recipients
    View official trial listing →
  • Completed NCT NCT01345708

    A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia

    Not yet reported Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico 23 participants Est. completion 2011-01 2 sites
    Other conditions: Autoimmune Hemolytic Disease (Cold Type) (Warm Type)
    View official trial listing →
  • Completed NCT NCT01358253

    Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

    Not yet reported Ruijin Hospital 100 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT01370772

    Intensified Rituimab Prephase Before FCR in Untreated B-CLL

    Not yet reported French Innovative Leukemia Organisation 140 participants Est. completion 2016-03 2 sites Stand-alone
    Other conditions: B-cell Chronic Lymphocytic Leukemia CLL
    View official trial listing →
  • Completed NCT NCT01397825

    MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

    Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 45 participants Est. completion 2016-10-05 25 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
    View official trial listing →
  • Completed NCT NCT01416974

    Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

    Not yet reported Memorial Sloan Kettering Cancer Center 13 participants Est. completion 2019-01-07 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT01424982

    Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 88 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT01451879

    Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

    University of Florida 11 participants Est. completion 2017-10 1 site
    Other conditions: Pompe Disease
    View official trial listing →
  • Completed NCT NCT01457144

    Study of Mantle Cell Lymphoma Treatment by RiBVD

    Not yet reported French Innovative Leukemia Organisation 76 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01493479

    Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

    Not yet reported The Christie NHS Foundation Trust 76 participants Est. completion 2015-11-06 7 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT01514344

    Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

    Not yet reported Andres J. M. Ferreri 20 participants Est. completion 2019-10 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT01516593

    Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma

    Not yet reported Andres J. M. Ferreri 19 participants Est. completion 2015-08 8 sites Stand-alone
    Other conditions: HIV, Burkitt's Lymphoma
    View official trial listing →
  • Completed NCT NCT01525836

    rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

    Not yet reported Shandong University 123 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Purpura, Idiopathic Thrombocytopenic Purpura
    View official trial listing →
  • Completed NCT NCT01538641

    Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

    Not yet reported Auxilio Mutuo Cancer Center 43 participants Est. completion 2008-12 Stand-alone
    Other conditions: Refractory Aggressive Non-Hodgkin's Lymphoma, Relapsing Aggressive Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT01539291

    Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

    Not yet reported Gilead Sciences 161 participants Est. completion 2018-06-29 45 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT01556347

    Multi-Drug Desensitization Protocol for Heart Transplant Candidates

    Not yet reported Providence Health & Services 2 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Heart Transplantation
    View official trial listing →
  • Completed NCT NCT01562977

    Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 82 participants Est. completion 2015-04 28 sites
    Other conditions: Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01596127

    Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2017-03-23 1 site Stand-alone
    Other conditions: Leukemia, Lymphoid Malignancies, Metastatic Malignant Neoplasm to the Leptomeninges
    View official trial listing →
  • Completed NCT NCT01609023

    A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia

    Hoffmann-La Roche 67 participants Est. completion 2015-11 9 sites
    Other conditions: Lymphocytic Leukemia, Chronic
    View official trial listing →
  • Completed NCT NCT01611090

    A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported Janssen Research & Development, LLC 578 participants Est. completion 2019-01-23 155 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT01613027

    An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

    Hoffmann-La Roche 135 participants Est. completion 2015-09 14 sites
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT01613599

    An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

    Genentech, Inc. 100 participants Est. completion 2017-04-28 15 sites
    Other conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
    View official trial listing →
  • Status unknown NCT NCT01619761

    NK Cells in Cord Blood Transplantation

    Not yet reported M.D. Anderson Cancer Center 13 participants Est. completion 2021-11 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
    View official trial listing →
  • Terminated NCT NCT01625741

    Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

    Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 6 participants Est. completion 2015-05 15 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01632124

    Rituximab-induced Pulmonary Function Changes

    University of Zurich 80 participants Est. completion 2013-12 1 site
    Other conditions: Rheumatoid Arthritis, Inflammatory Myositis
    View official trial listing →
  • Completed NCT NCT01638715

    A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

    Not yet reported Medical University of Vienna 115 participants Est. completion 2018-08-01 9 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Active, not recruiting NCT NCT01661881

    Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

    Not yet reported Christine Ryan 23 participants Est. completion 2030-04 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01662102

    Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

    Not yet reported Spectrum Pharmaceuticals, Inc 1 participants Est. completion 2013-03-05 5 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01670812

    Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 100 participants Est. completion 2014-06 14 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01676558

    A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

    Not yet reported Korea Cancer Center Hospital 24 participants Est. completion 2017-06 2 sites Stand-alone
    Other conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01678404

    131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

    Not yet reported Korea Cancer Center Hospital 28 participants Est. completion 2016-09 1 site Stand-alone
    Other conditions: Relapsed or Refractory Marginal Zone B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01719159

    Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

    Not yet reported Anders Svenningsson 23 participants Est. completion 2016-06 2 sites Stand-alone
    Other conditions: Progressive Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01723839

    Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide

    Not yet reported Hackensack Meridian Health 21 participants Est. completion 2021-06-08 1 site
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Terminated NCT NCT01724294

    An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma

    Hoffmann-La Roche 113 participants Est. completion 2016-04 1 site
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01727232

    Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

    Henri Mondor University Hospital 107 participants Est. completion 2012-10
    Other conditions: Primary Immune Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT01729104

    Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2018-10-03 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01729806

    Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 32 participants Est. completion 2018-03-30 7 sites Stand-alone
    Other conditions: CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT01730495

    Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome

    Not yet reported Haukeland University Hospital 4 participants Est. completion 2014-08 1 site
    Other conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
    View official trial listing →
  • Completed NCT NCT01742988

    Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

    Not yet reported Curis, Inc. 106 participants Est. completion 2020-10-09 11 sites Stand-alone
    Other conditions: Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL)
    View official trial listing →
  • Withdrawn NCT NCT01754870

    Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

    Not yet reported University of Wisconsin, Madison Est. completion 2014-08 Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Completed NCT NCT01759030

    Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis

    Not yet reported Biocad 181 participants Est. completion 2015-07 40 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT01765842

    Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy

    Not yet reported Fundación Pública Andaluza Progreso y Salud 9 participants Est. completion 2015-12 3 sites Stand-alone
    Other conditions: Lupus Nephritis
    View official trial listing →
  • Completed NCT NCT01776840

    A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported Janssen Research & Development, LLC 523 participants Est. completion 2024-06-24 201 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01808911

    Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)

    Not yet reported University Hospital, Rouen 110 participants Est. completion 2021-01-14 34 sites Stand-alone
    Other conditions: Acquired Haemophilia
    View official trial listing →
  • Terminated NCT NCT01812005

    Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Not yet reported Ohio State University Comprehensive Cancer Center 14 participants Est. completion 2017-04-20 2 sites Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Status unknown NCT NCT01828008

    Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

    Han weidong 20 participants Est. completion 2015-05
    Other conditions: Lymphomas
    View official trial listing →
  • Completed NCT NCT01842386

    Rituximab for Anti-cytokine Autoantibody-Associated Diseases

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 7 participants Est. completion 2021-05-06 1 site Stand-alone
    Other conditions: Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
    View official trial listing →
  • Completed NCT NCT01859819

    Treatment for Advanced B-Cell Lymphoma

    Not yet reported New York Medical College 45 participants Est. completion 2021-06 5 sites Stand-alone
    Other conditions: Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01871675

    Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

    Not yet reported SCRI Development Innovations, LLC 48 participants Est. completion 2016-06 4 sites Stand-alone
    Other conditions: Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01939327

    Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma

    Not yet reported Institut Paoli-Calmettes 34 participants Est. completion 2020-01 1 site Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01980654

    Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

    Not yet reported Pharmacyclics LLC. 80 participants Est. completion 2017-11 12 sites Stand-alone
    Other conditions: Follicular Lymphoma, B-cell Lymphoma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT01980888

    Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

    Not yet reported Gilead Sciences 311 participants Est. completion 2016-06-16 91 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01987505

    MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

    Not yet reported Hoffmann-La Roche 140 participants Est. completion 2017-04-11 39 sites Stand-alone
    Other conditions: Lymphoma, Non Hodgkin
    View official trial listing →
  • Completed NCT NCT01994382

    Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

    Not yet reported, Not yet reported Alexion Pharmaceuticals, Inc. 260 participants Est. completion 2020-12-15 23 sites Stand-alone
    Other conditions: Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
    View official trial listing →
  • Completed NCT NCT01994850

    Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

    Not yet reported, Not yet reported Abramson Cancer Center at Penn Medicine 32 participants Est. completion 2019-01 1 site Stand-alone
    Other conditions: CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT01998893

    A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

    Not yet reported Hoffmann-La Roche 38 participants Est. completion 2008-02 11 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02003222

    Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

    Not yet reported National Cancer Institute (NCI) 488 participants Est. completion 2027-02-25 544 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
    View official trial listing →
  • Completed NCT NCT02006706

    A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy

    Not yet reported Hoffmann-La Roche 15 participants Est. completion 2007-11-23 3 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT02012088

    Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 91 participants Est. completion 2021-08 14 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT02040116

    Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

    Not yet reported Wake Forest University Health Sciences 19 participants Est. completion 2014-08 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT02043587

    Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

    Not yet reported University of California, San Diego 31 participants Est. completion 2022-04-14 4 sites Stand-alone
    Other conditions: Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
    View official trial listing →
  • Completed NCT NCT02049541

    Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

    Not yet reported Kami Maddocks, MD 18 participants Est. completion 2019-04-09 2 sites Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT02050581

    A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone

    Weill Medical College of Cornell University 72 participants 1 site
    Other conditions: Idiopathic Thrombocytopenia Purpura
    View official trial listing →
  • Withdrawn NCT NCT02054559

    R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL

    Not yet reported Asan Medical Center Est. completion 2020-01 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02077166

    Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported, Not yet reported Pharmacyclics LLC. 138 participants Est. completion 2020-12-17 40 sites Stand-alone
    Other conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02097745

    A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

    Not yet reported Hoffmann-La Roche 341 participants Est. completion 2013-06 97 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT02115997

    A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

    Not yet reported Hoffmann-La Roche 30 participants Est. completion 2022-06-07 10 sites Stand-alone
    Other conditions: Wegener's Granulomatosis or Microscopic Polyangiitis
    View official trial listing →
  • Completed NCT NCT02122406

    Depression and Anxiety in Rheumatoid Arthritis

    University of Pavia 200 participants Est. completion 2015-12 1 site
    Other conditions: Rheumatoid Arthritis, Depression, Anxiety
    View official trial listing →
  • Completed NCT NCT02128061

    Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

    Not yet reported The Lymphoma Academic Research Organisation 250 participants Est. completion 2021-01 97 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Approved For Marketing NCT NCT02136511

    Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

    Gilead Sciences 8 sites
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Status unknown NCT NCT02142335

    Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

    Not yet reported California Cancer Assocaties for Research & Excellence 17 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Malignant Melanoma of Skin Stage III, Metastatic Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT02171104

    MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

    Not yet reported Masonic Cancer Center, University of Minnesota 149 participants Est. completion 2029-07-14 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
    View official trial listing →
  • Withdrawn NCT NCT02194374

    Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

    Not yet reported M.D. Anderson Cancer Center Est. completion 2017-06 Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT02199184

    Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2023-02-17 1 site Stand-alone
    Other conditions: AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
    View official trial listing →
  • Completed NCT NCT02222155

    Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

    Not yet reported Amgen 42 participants Est. completion 2016-07-19 43 sites
    Other conditions: ANCA-associated Vasculitis
    View official trial listing →
  • Completed NCT NCT02229942

    B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.

    Not yet reported Haukeland University Hospital 151 participants Est. completion 2017-11 5 sites Stand-alone
    Other conditions: Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME)
    View official trial listing →
  • Completed NCT NCT02257242

    Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

    Not yet reported Brown University 11 participants Est. completion 2020-11-18 1 site Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
    View official trial listing →
  • Completed NCT NCT02257567

    A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

    Not yet reported, Not yet reported Hoffmann-La Roche 331 participants Est. completion 2021-10-21 62 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02267915

    Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 36 participants Est. completion 2020-02 15 sites Stand-alone
    Other conditions: Mantle-cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02315118

    Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

    Not yet reported, Not yet reported National University Hospital, Singapore 18 participants Est. completion 2018-12 1 site Stand-alone
    Other conditions: B-Cell Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT02316691

    B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

    University of Pittsburgh 2 participants Est. completion 2019-11 1 site
    Other conditions: Thyroid Eye Disease
    View official trial listing →
  • Completed NCT NCT02343536

    A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

    Not yet reported Celgene 59 participants Est. completion 2020-01-29 7 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
    View official trial listing →
  • Status unknown NCT NCT02354846

    An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)

    Yonsei University 112 participants Est. completion 2021-03 1 site
    Other conditions: B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02381899

    Observational Study in CLL Patients Receiving BR

    Czech CLL Study Group 83 participants Est. completion 2018-12 5 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02394119

    Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome

    Not yet reported Istituto Giannina Gaslini 140 participants Est. completion 2019-05 1 site
    Other conditions: Nephrotic Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT02414022

    Economic Analysis of Alliance A041202 CLL Study

    Canadian Cancer Trials Group 55 participants Est. completion 2026-12-31 15 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT02419469

    Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Not yet reported M.D. Anderson Cancer Center 1 participants Est. completion 2017-06-22 1 site Stand-alone
    Other conditions: Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
    View official trial listing →
  • Completed NCT NCT02423915

    Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention

    Not yet reported M.D. Anderson Cancer Center 5 participants Est. completion 2020-10-06 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT02438982

    Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome

    Not yet reported Nilratan Sircar Medical College 120 participants Est. completion 2016-09 1 site Stand-alone
    Other conditions: Nephrotic Syndrome
    View official trial listing →
  • Terminated NCT NCT02451111

    Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

    Not yet reported Swiss Cancer Institute 190 participants Est. completion 2023-07-15 42 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02461316

    Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia

    Hoffmann-La Roche 22 participants Est. completion 2011-12 3 sites
    Other conditions: Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer
    View official trial listing →
  • Completed NCT NCT02545959

    Intrathecal Rituximab in Progressive Multiple Sclerosis

    Not yet reported Centre Hospitalier de PAU 10 participants Est. completion 2019-09-02 1 site Stand-alone
    Other conditions: Multiple Sclerosis, Chronic Progressive, Nervous System Diseases
    View official trial listing →
  • Completed NCT NCT02569996

    A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

    Not yet reported Hoffmann-La Roche 124 participants Est. completion 2013-08 21 sites Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Terminated NCT NCT02592876

    Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

    Not yet reported Seagen Inc. 81 participants Est. completion 2018-04-20 29 sites Stand-alone
    Other conditions: Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b, Follicular Lymphoma, Grade 3b
    View official trial listing →
  • Completed NCT NCT02594384

    A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

    Not yet reported OrphAI Therapeutics 62 participants Est. completion 2023-03-30 11 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
    View official trial listing →
  • Withdrawn NCT NCT02623920

    Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported University of Arizona Est. completion 2017-05-17 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02689986

    Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

    Not yet reported Helse Fonna 43 participants Est. completion 2016-12 8 sites Stand-alone
    Other conditions: Cold Agglutinin Disease, Autoimmune Hemolytic Anemia
    View official trial listing →
  • Terminated NCT NCT02703272

    A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

    Not yet reported Janssen Research & Development, LLC 72 participants Est. completion 2021-06-11 76 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT02729896

    A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Hoffmann-La Roche 36 participants Est. completion 2019-10-07 19 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02734771

    A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported Patrick Reagan 24 participants Est. completion 2025-12 2 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02744196

    Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis

    Not yet reported Biocad 159 participants Est. completion 2017-08 Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT02747043

    Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

    Not yet reported Amgen 256 participants Est. completion 2019-06-28 98 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Status unknown NCT NCT02767674

    Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 258 participants Est. completion 2020-12 6 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT02789397

    Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

    Not yet reported Medical College of Wisconsin Est. completion 2018-03-06
    Other conditions: Granulomatous and Lymphocytic Interstitial Lung Disease
    View official trial listing →
  • Status unknown NCT NCT02834468

    DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients

    Not yet reported Shandong University 100 participants Est. completion 2018-12 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT02855359

    Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

    Not yet reported Seagen Inc. 24 participants Est. completion 2018-05-15 35 sites Stand-alone
    Other conditions: Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
    View official trial listing →
  • Completed NCT NCT02858804

    EDOCH Alternating With DHAP for New Diagnosed Younger MCL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 55 participants Est. completion 2020-06 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02900976

    Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

    Not yet reported Children's Oncology Group 18 participants Est. completion 2025-12-31 38 sites Stand-alone
    Other conditions: EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
    View official trial listing →
  • Status unknown NCT NCT02927717

    An Italian Experience on Grade 3b Follicular Lymphoma

    A.O.U. Città della Salute e della Scienza 60 participants Est. completion 2017-05
    Other conditions: Grade 3b Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02947347

    Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

    Not yet reported Pharmacyclics LLC. 445 participants Est. completion 2025-06-09 128 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02955823

    A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

    Not yet reported Fondazione Italiana Linfomi - ETS 68 participants Est. completion 2022-11-24 18 sites Stand-alone
    Other conditions: Diffuse Large B-cells Non-Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02970318

    A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

    Not yet reported Acerta Pharma BV 310 participants Est. completion 2027-10-01 157 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT02993536

    Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

    Abramson Cancer Center at Penn Medicine 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT03002038

    Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients

    Not yet reported, Not yet reported Isfahan University of Medical Sciences 86 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Neuromyelitis Optica Spectrum Disorder
    View official trial listing →
  • Completed NCT NCT03003546

    Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

    Not yet reported Mayo Clinic 9 participants Est. completion 2023-05-16 1 site Stand-alone
    Other conditions: Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03018626

    R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

    Not yet reported Nanfang Hospital, Southern Medical University 402 participants Est. completion 2021-01 1 site Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Completed NCT NCT03019640

    Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2021-08-16 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03036904

    Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

    Not yet reported Weill Medical College of Cornell University 31 participants Est. completion 2021-11-11 6 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03087929

    Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon

    Sunnybrook Health Sciences Centre 12 participants Est. completion 2017-03-15 1 site
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT03112603

    A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

    Not yet reported Incyte Corporation 330 participants Est. completion 2022-12-15 191 sites
    Other conditions: Graft-versus-host Disease (GVHD)
    View official trial listing →
  • Completed NCT NCT03129828

    Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

    Not yet reported, Not yet reported Prof. Dr. Clemens Schmitt 38 participants Est. completion 2024-11-12 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03131934

    Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant

    Not yet reported University College, London 4 participants Est. completion 2026-03-12 2 sites Stand-alone
    Other conditions: Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
    View official trial listing →
  • Status unknown NCT NCT03151044

    R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL

    Not yet reported FENG Ji-feng 408 participants Est. completion 2017-07 9 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03180723

    Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis

    Not yet reported Assiut University 30 participants Est. completion 2019-12 Stand-alone
    Other conditions: Membranoproliferative Glomerulonephritis
    View official trial listing →
  • Terminated NCT NCT03189836

    Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

    Not yet reported Cogent Biosciences, Inc. 26 participants Est. completion 2020-09-21 11 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT03225924

    Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

    Not yet reported, Not yet reported The Lymphoma Academic Research Organisation 25 participants Est. completion 2019-10-18 27 sites Stand-alone
    Other conditions: DLBCL
    View official trial listing →
  • Completed NCT NCT03236857

    A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

    Not yet reported AbbVie 143 participants Est. completion 2023-04-19 31 sites Stand-alone
    Other conditions: Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
    View official trial listing →
  • Terminated NCT NCT03269552

    Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

    Not yet reported University of Washington 4 participants Est. completion 2018-12-28 1 site Stand-alone
    Other conditions: Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT03289182

    An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

    Hoffmann-La Roche 701 participants Est. completion 2020-10-27 25 sites
    Other conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Status unknown NCT NCT03293173

    Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

    Not yet reported Nordic Lymphoma Group 120 participants Est. completion 2024-12-31 16 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Status unknown NCT NCT03318835

    Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

    Not yet reported Fudan University 162 participants Est. completion 2020-08-22 1 site Stand-alone
    Other conditions: Thalidomide
    View official trial listing →
  • Active, not recruiting NCT NCT03323476

    Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

    Not yet reported Centre Hospitalier Departemental Vendee 136 participants Est. completion 2031-03 57 sites
    Other conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease
    View official trial listing →
  • Completed NCT NCT03366272

    Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

    Not yet reported, Not yet reported Universität des Saarlandes 348 participants Est. completion 2025-01-15 77 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Status unknown NCT NCT03443570

    Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

    Not yet reported Shandong University 200 participants Est. completion 2021-03-01 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT03455517

    Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 77 participants Est. completion 2023-05-11 31 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03485118

    RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

    Not yet reported Zhejiang Hisun Pharmaceutical Co. Ltd. 137 participants Est. completion 2018-01-14
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03505944

    Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported, Not yet reported Nordic Lymphoma Group 59 participants Est. completion 2022-12-01 17 sites Stand-alone
    Other conditions: Relapsed Non Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03514979

    Acquired Immunodeficiency in ANCA Associated Vasculitis

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 114 participants Est. completion 2022-12-14 1 site Stand-alone
    Other conditions: Systemic Vasculitis
    View official trial listing →
  • Terminated NCT NCT03518112

    Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 6 participants Est. completion 2021-05-27 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT03530683

    A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

    Not yet reported Pfizer 189 participants Est. completion 2024-07-18 62 sites
    Other conditions: Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03545035

    Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

    Gruppo Italiano Malattie EMatologiche dell'Adulto 104 participants Est. completion 2020-10-28 38 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT03578198

    Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

    Not yet reported Seoul National University Hospital 12 participants Est. completion 2022-04-07 1 site Stand-alone
    Other conditions: CD20-positive Non-Hodgkin Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT03639324

    Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

    Not yet reported Virginia Commonwealth University Est. completion 2021-10-18
    Other conditions: Chronic Lymphocytic Leukemia, CLL, Relapsed CLL, Refractory Chronic Lymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, SLL, Relapsed Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03650933

    A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

    Not yet reported Nanjing Yoko Biomedical Co., Ltd. 360 participants Est. completion 2025-12-31 1 site
    Other conditions: Diffuse Large B-Cell Lymphoma, Unspecified Site
    View official trial listing →
  • Completed NCT NCT03663894

    Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era

    Hospices Civils de Lyon 95 participants Est. completion 2018-07-31 1 site
    Other conditions: Patient's Outcome Prognostic Factors
    View official trial listing →
  • Active, not recruiting NCT NCT03710772

    Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 51 participants Est. completion 2027-03-22 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03715309

    R2 in the Treatment of Follicular Lymphoma

    Not yet reported Ruijin Hospital 115 participants Est. completion 2020-11-01 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT03783403

    A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

    Not yet reported Celgene 206 participants Est. completion 2024-08-05 31 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Status unknown NCT NCT03791827

    Multicenter Registry of Pediatric Lupus Nephritis in China

    Xiqiang Dang 1200 participants Est. completion 2024-11-30 1 site
    Other conditions: Lupus Nephritis, Children, Steroid, Immunosuppressive Treatment
    View official trial listing →
  • Status unknown NCT NCT03795571

    Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 12 participants Est. completion 2019-12-31 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
    View official trial listing →
  • Status unknown NCT NCT03837873

    DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 118 participants Est. completion 2024-09-01 6 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03847727

    Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia

    Pirogov Russian National Research Medical University 112 participants Est. completion 2020-12-03 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT03920722

    Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis

    Not yet reported Assistance Publique - Hôpitaux de Paris 8 participants Est. completion 2023-09-06 1 site Stand-alone
    Other conditions: Microscopic Polyangiitis (MPA)
    View official trial listing →
  • Active, not recruiting NCT NCT03930953

    A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

    Not yet reported, Not yet reported Celgene 438 participants Est. completion 2028-02-09 66 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT03934814

    Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

    Not yet reported I-Mab Biopharma US Limited 98 participants Est. completion 2023-01-10 21 sites Stand-alone
    Other conditions: Solid Tumor, Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03984448

    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

    Not yet reported, Not yet reported National Cancer Institute (NCI) 363 participants Est. completion 2028-04-01 634 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03997968

    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

    Not yet reported, Not yet reported Cyteir Therapeutics, Inc. 169 participants Est. completion 2024-12-20 16 sites Stand-alone
    Other conditions: Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04002297

    A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

    Not yet reported BeOne Medicines 510 participants Est. completion 2031-09-30 176 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04023916

    Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

    Not yet reported Chinese Academy of Medical Sciences 30 participants Est. completion 2021-07-30 Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Sintilimab, TP53 Mutation
    View official trial listing →
  • Completed NCT NCT04033276

    IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies

    Not yet reported Seoul National University Hospital 50 participants Est. completion 2022-05-03 2 sites
    Other conditions: Renal Transplant
    View official trial listing →
  • Terminated NCT NCT04047797

    Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2025-04-11 1 site Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04083014

    Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

    Not yet reported Peking Union Medical College Hospital 33 participants Est. completion 2024-03-20 1 site
    Other conditions: Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT04094142

    Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported Seoul National University Hospital 66 participants Est. completion 2022-05-15 1 site Stand-alone
    Other conditions: Non-hodgkin Lymphoma,B Cell
    View official trial listing →
  • Status unknown NCT NCT04120350

    R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty

    Not yet reported, Not yet reported Peking Union Medical College Hospital 47 participants Est. completion 2024-08 1 site Stand-alone
    Other conditions: Primary Central Nervous System Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04129710

    A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 120 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
    View official trial listing →
  • Completed NCT NCT04164368

    Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

    Not yet reported Fudan University 67 participants Est. completion 2023-08-30 1 site Stand-alone
    Other conditions: Double Expressor Lymphoma
    View official trial listing →
  • Completed NCT NCT04189588

    Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

    Not yet reported TerSera Therapeutics LLC 34 participants Est. completion 2020-12-23 7 sites
    Other conditions: Oncology Patients Receiving Chemotherapy
    View official trial listing →
  • Completed NCT NCT04214444

    Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab

    Not yet reported University Hospital, Tours 26 participants Est. completion 2025-05-14 1 site
    Other conditions: Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Status unknown NCT NCT04246359

    Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

    Not yet reported Huiqiang Huang 52 participants Est. completion 2023-01-16 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Status unknown NCT NCT04251741

    Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment

    Not yet reported Reade Rheumatology Research Institute 86 participants Est. completion 2024-05-01 2 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT04268771

    A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

    Not yet reported Dr. Reddy's Laboratories Limited 140 participants Est. completion 2022-04-20 26 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT04283747

    Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis

    Mazandaran University of Medical Sciences 170 participants Est. completion 2022-12 1 site
    Other conditions: Multiple Sclerosis, Hypogammaglobulinemia
    View official trial listing →
  • Completed NCT NCT04369183

    Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

    Istanbul University 25 participants Est. completion 2020-10-31 1 site
    Other conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease
    View official trial listing →
  • Status unknown NCT NCT04400045

    Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

    Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 10 participants Est. completion 2023-05 1 site Stand-alone
    Other conditions: Nijmegen Breakage Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT04400994

    IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

    Not yet reported The University of Hong Kong 20 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Pemphigus
    View official trial listing →
  • Terminated NCT NCT04402580

    Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

    Not yet reported Istituto Giannina Gaslini 30 participants Est. completion 2020-08-31 1 site Stand-alone
    Other conditions: Nephrotic Syndrome Steroid-Dependent
    View official trial listing →
  • Active, not recruiting NCT NCT04458610

    Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2027-05-26 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04460248

    Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

    Not yet reported Ruijin Hospital 40 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04480450

    Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy

    Not yet reported University of Kansas Medical Center Est. completion 2025-09
    Other conditions: Chronic Inflammatory Demyelinating Polyneuropathy
    View official trial listing →
  • Active, not recruiting NCT NCT04540380

    Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

    Not yet reported Massachusetts General Hospital 20 participants Est. completion 2027-06 1 site
    Other conditions: Renal Failure
    View official trial listing →
  • Status unknown NCT NCT04542629

    Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children

    Not yet reported Assiut University 140 participants Est. completion 2022-08-20 Stand-alone
    Other conditions: Refractory Epilepsy
    View official trial listing →
  • Active, not recruiting NCT NCT04542824

    Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

    Not yet reported, Not yet reported Genmab 78 participants Est. completion 2027-09 15 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04544059

    Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

    Not yet reported Nanfang Hospital, Southern Medical University 87 participants Est. completion 2024-10-01 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04578613

    ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

    Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 218 participants Est. completion 2025-06-30 56 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT04585893

    Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi

    Not yet reported UNC Lineberger Comprehensive Cancer Center 15 participants Est. completion 2026-06-07 1 site Stand-alone
    Other conditions: Multicentric Castleman Disease
    View official trial listing →
  • Status unknown NCT NCT04610242

    Prediction of Rituximab Hypersensitivity and Desensitization Treatment

    Not yet reported Peking Union Medical College Hospital 30 participants Est. completion 2020-12-31 1 site Stand-alone
    Other conditions: Drug Hypersensitivity Reaction
    View official trial listing →
  • Status unknown NCT NCT04624893

    A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

    Jiangsu Cancer Institute & Hospital 35 participants Est. completion 2020-12 1 site
    Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
    View official trial listing →
  • Status unknown NCT NCT04640818

    Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

    Claudio Gobbi 45 participants Est. completion 2022-10-31 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT04660799

    A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported Hoffmann-La Roche 50 participants Est. completion 2022-10-11 8 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Active, not recruiting NCT NCT04661007

    To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

    Not yet reported, Not yet reported Incyte Biosciences Japan GK 72 participants Est. completion 2026-12-31 23 sites Stand-alone
    Other conditions: Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04671420

    Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.

    Not yet reported Shanghai Henlius Biotech Est. completion 2022-10
    Other conditions: CD20-positive Follicular Lymphoma, With Low Tumour Burden
    View official trial listing →
  • Terminated NCT NCT04743739

    Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN

    Not yet reported Peking Union Medical College Hospital 12 participants Est. completion 2024-12-20 7 sites Stand-alone
    Other conditions: Idiopathic Membranous Nephropathy
    View official trial listing →
  • Withdrawn NCT NCT04796922

    To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

    Not yet reported Incyte Corporation Est. completion 2032-08-25 Stand-alone
    Other conditions: Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
    View official trial listing →
  • Status unknown NCT NCT04835870

    Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

    Not yet reported The First Affiliated Hospital of Soochow University 78 participants Est. completion 2025-10-01 16 sites Stand-alone
    Other conditions: Non-GCB/ABC Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04842318

    Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

    Not yet reported Ruijin Hospital 789 participants Est. completion 2024-03-01 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04880577

    Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

    Not yet reported Massachusetts General Hospital Est. completion 2025-02-14 1 site
    Other conditions: Multiple Sclerosis, Relapsing-Remitting, Fatigue
    View official trial listing →
  • Active, not recruiting NCT NCT04884035

    Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

    Not yet reported Celgene 224 participants Est. completion 2028-12-01 36 sites Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT04918940

    Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma

    Not yet reported Centre Henri Becquerel 20 participants Est. completion 2022-06-27 1 site
    Other conditions: Follicular Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04947319

    Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

    Not yet reported Ono Pharmaceutical Co., Ltd. 119 participants Est. completion 2027-03-31 39 sites Stand-alone
    Other conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04965493

    A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Not yet reported Loxo Oncology, Inc. 600 participants Est. completion 2027-10 176 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04980859

    Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation

    Not yet reported Nanfang Hospital, Southern Medical University 45 participants Est. completion 2025-09-01 Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05004064

    Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

    Not yet reported University College, London 48 participants Est. completion 2028-06-08 12 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT05051891

    A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

    Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 3 participants Est. completion 2025-06-30 22 sites Stand-alone
    Other conditions: Treatment-naїve Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05078177

    Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

    Not yet reported St. Petersburg State Pavlov Medical University 40 participants Est. completion 2024-12-21 1 site Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT05156710

    BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

    Not yet reported Sanofi 48 participants Est. completion 2026-10-20 27 sites Stand-alone
    Other conditions: Transplant Rejection
    View official trial listing →
  • Status unknown NCT NCT05189197

    A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

    Not yet reported Fudan University 41 participants Est. completion 2026-01 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma(DLBCL)
    View official trial listing →
  • Status unknown NCT NCT05287984

    Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 63 participants Est. completion 2024-11-29 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
    View official trial listing →
  • Status unknown NCT NCT05290090

    ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

    Not yet reported Zhejiang Cancer Hospital 31 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT05293509

    Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

    Not yet reported M.D. Anderson Cancer Center Est. completion 2023-09-18 1 site Stand-alone
    Other conditions: Stem Cell Transplantation
    View official trial listing →
  • Active, not recruiting NCT NCT05371093

    Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

    Not yet reported Kite, A Gilead Company 231 participants Est. completion 2030-10 52 sites
    Other conditions: Relapsed/Refractory Follicular Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05376709

    A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population

    Not yet reported National Taiwan University Hospital 200 participants Est. completion 2024-01-01 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Active, not recruiting NCT NCT05409066

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

    Not yet reported Genmab 549 participants Est. completion 2029-12 273 sites Stand-alone
    Other conditions: Follicular Lymphoma (FL)
    View official trial listing →
  • Not yet recruiting NCT NCT05415579

    Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)

    Dongzhimen Hospital, Beijing 2000 participants Est. completion 2030-05-31
    Other conditions: Demyelinating Diseases of the Central Nervous System (DDC)
    View official trial listing →
  • Active, not recruiting NCT NCT05455697

    Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

    Not yet reported, Not yet reported University of Washington 33 participants Est. completion 2027-01-07 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT05487703

    A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting

    Pfizer 318 participants Est. completion 2022-12-23 1 site
    Other conditions: Arthritis, Rheumatoid
    View official trial listing →
  • Terminated NCT NCT05498220

    Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 5 participants Est. completion 2025-10-03 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05498259

    Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

    Not yet reported The First Affiliated Hospital of Soochow University 46 participants Est. completion 2025-01-01 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05527912

    A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

    Not yet reported Sun Yat-sen University 45 participants Est. completion 2024-12-01 2 sites Stand-alone
    Other conditions: Double Express Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05533164

    Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse

    Not yet reported Sint Maartenskliniek 174 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Polymyalgia Rheumatica
    View official trial listing →
  • Status unknown NCT NCT05644210

    Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

    Qilu Hospital of Shandong University 80 participants Est. completion 2025-12-30 1 site
    Other conditions: Antiphospholipid Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT05683171

    A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 16 participants Est. completion 2027-09-30 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05768061

    HBV Reactivation in Anti CD20 Treatment

    HaEmek Medical Center, Israel 5000 participants Est. completion 2023-12 1 site
    Other conditions: Hepatitis B
    View official trial listing →
  • Status unknown NCT NCT05777369

    R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 30 participants Est. completion 2024-08 Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05782933

    Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy

    Not yet reported Beijing Friendship Hospital 2 participants Est. completion 2023-12-04 1 site Stand-alone
    Other conditions: Idiopathic Membranous Nephropathy
    View official trial listing →
  • Status unknown NCT NCT05824390

    A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

    Not yet reported XIEJINGYUAN 116 participants Est. completion 2023-10-01 1 site Stand-alone
    Other conditions: IgA Nephropathy
    View official trial listing →
  • Active, not recruiting NCT NCT05888493

    A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

    Not yet reported Novartis Pharmaceuticals 109 participants Est. completion 2031-02-20 30 sites
    Other conditions: Follicular Lymphoma (FL)
    View official trial listing →
  • Status unknown NCT NCT05923879

    Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

    Ruijin Hospital 30 participants Est. completion 2025-06-30 1 site
    Other conditions: Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Withdrawn NCT NCT05934097

    FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

    Not yet reported Fate Therapeutics Est. completion 2039-05 Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT05963048

    Rituxmab Versus IL-6 in Treating ILD

    Not yet reported, Not yet reported Assiut University 60 participants Est. completion 2023-06-01 1 site Stand-alone
    Other conditions: Interstitial Lung Disease, Scleroderma
    View official trial listing →
  • Active, not recruiting NCT NCT06040320

    Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

    Not yet reported, Not yet reported Washington University School of Medicine 12 participants Est. completion 2032-05-31 1 site Stand-alone
    Other conditions: Post-transplant Lymphoproliferative Disorder
    View official trial listing →
  • Status unknown NCT NCT06068829

    Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

    Feng Jinzhou 80 participants Est. completion 2025-06-30
    Other conditions: Neuromyelitis Optica Spectrum Disorders
    View official trial listing →
  • Terminated NCT NCT06078696

    Siplizumab for Sickle Cell Disease Transplant

    Not yet reported, Not yet reported Columbia University 1 participants Est. completion 2025-12-11 1 site Stand-alone
    Other conditions: Anemia, Sickle Cell
    View official trial listing →
  • Status unknown NCT NCT06104553

    A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

    Not yet reported, Not yet reported Shanghai Hengrui Pharmaceutical Co., Ltd. 132 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: B-cell Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT06190457

    Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 16 participants Est. completion 2022-08-30
    Other conditions: Lymphoma, Non-Hodgkin, Child, Only
    View official trial listing →
  • Withdrawn NCT NCT06205290

    A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Est. completion 2031-10-13 48 sites
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Active, not recruiting NCT NCT06230224

    A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

    Not yet reported Regeneron Pharmaceuticals 216 participants Est. completion 2029-05-29 81 sites
    Other conditions: B-Cell Non-Hodgkin Lymphoma (B-NHL)
    View official trial listing →
  • Not yet recruiting NCT NCT06255704

    A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

    Not yet reported Shanxi Province Cancer Hospital 23 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06265220

    AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

    Not yet reported Artiva Biotherapeutics, Inc. 51 participants Est. completion 2027-08 9 sites Stand-alone
    Other conditions: Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
    View official trial listing →
  • Withdrawn NCT NCT06313996

    A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Est. completion 2031-10-16
    Other conditions: Relapsed or Refractory Follicular Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06321601

    Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

    Not yet reported Amgen 19 participants Est. completion 2027-07-18 34 sites
    Other conditions: Vasculitis
    View official trial listing →
  • Completed NCT NCT06362044

    A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

    AbbVie 89 participants Est. completion 2024-12-31 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT06516978

    A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 528 participants Est. completion 2029-04-01 Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06652152

    Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma

    Ruijin Hospital 400 participants Est. completion 2025-12-30
    Other conditions: Diffuse Large B Cell Lymphoma (DLBCL), Double Expressor Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06655896

    Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

    Not yet reported Novartis Pharmaceuticals 96 participants Est. completion 2032-08-30 93 sites
    Other conditions: Scleroderma, Diffuse
    View official trial listing →
  • Status unknown NCT NCT06711354

    B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment

    Region Stockholm 111 participants Est. completion 2025-12
    Other conditions: Multiple Sclerosis, B-Cell Deficiency, Offspring, Adult, Immunosuppression, Pregnancy Related
    View official trial listing →
  • Status unknown NCT NCT06832228

    Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL

    Not yet reported Zhejiang Cancer Hospital 30 participants Est. completion 2026-09-01 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma (DLBCL)
    View official trial listing →
  • Not yet recruiting NCT NCT06901999

    Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients

    Not yet reported Ruijin Hospital 23 participants Est. completion 2028-11 Stand-alone
    Other conditions: CNS Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06942507

    Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

    Not yet reported Peking Union Medical College Hospital 104 participants Est. completion 2029-04-30 1 site Stand-alone
    Other conditions: Waldenström's Macroglobulinemia (WM)
    View official trial listing →
  • Not yet recruiting NCT NCT07010302

    Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

    Not yet reported Massachusetts General Hospital 540 participants Est. completion 2030-05 3 sites
    Other conditions: NMOSD
    View official trial listing →
  • Not yet recruiting NCT NCT07029139

    A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

    Not yet reported Shanghai JMT-Bio Inc. 156 participants Est. completion 2029-03-01 Stand-alone
    Other conditions: Primary Membranous Nephropathy
    View official trial listing →
  • Active, not recruiting NCT NCT07071246

    Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

    Not yet reported Tang-Du Hospital 30 participants Est. completion 2027-07-31 1 site
    Other conditions: Treatment
    View official trial listing →
  • Not yet recruiting NCT NCT07259122

    A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 43 participants Est. completion 2032-06-30 2 sites Stand-alone
    Other conditions: Waldenström Macroglobulinemia (WM)
    View official trial listing →
  • Not yet recruiting NCT NCT07416942

    Omics of Rituximab-resistance

    Mario Negri Institute for Pharmacological Research 120 participants Est. completion 2029-03 1 site
    Other conditions: Membranous Nephropathy
    View official trial listing →
  • Not yet recruiting NCT NCT07505849

    ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma

    Not yet reported KeshuZhou 100 participants Est. completion 2030-03-23 Stand-alone
    Other conditions: Follicular Lymphomas
    View official trial listing →
  • Not yet recruiting NCT NCT07588698

    Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

    Not yet reported Carrie Ho, MD 20 participants Est. completion 2029-08-31 2 sites Stand-alone
    Other conditions: Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
    View official trial listing →
  • Not yet recruiting NCT NCT07608731

    Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas

    Not yet reported Allison Winter 18 participants Est. completion 2029-09 1 site Stand-alone
    Other conditions: Large B-cell Lymphoma, Central Nervous System Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07638787

    Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL

    Not yet reported, Not yet reported Ruijin Hospital 40 participants Est. completion 2029-04-30 1 site Stand-alone
    Other conditions: Large B-cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07674745

    Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

    Not yet reported University of Alabama at Birmingham 52 participants Est. completion 2031-03-31 9 sites Stand-alone
    Other conditions: Idiopathic Pulmonary Fibrosis
    View official trial listing →
  • Not yet recruiting NCT NCT07677813

    Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

    Not yet reported Ou Bai, MD/PHD 66 participants Est. completion 2031-12-31 1 site Stand-alone
    Other conditions: DLBCL - Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07694414

    Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

    Not yet reported Inge Marie Svane 25 participants Est. completion 2028-12-01 1 site Stand-alone
    Other conditions: Immune-Related Adverse Events
    View official trial listing →
  • Not yet recruiting NCT NCT07697339

    HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 40 participants Est. completion 2028-12-01 Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07736950

    A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

    Not yet reported Australasian Leukaemia and Lymphoma Group 138 participants Est. completion 2035-01-13
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07760610

    Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response

    Not yet reported The First Hospital of Jilin University 27 participants Est. completion 2029-07 Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
    View official trial listing →
  • Not yet recruiting NCT NCT07769333

    Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus Vulgaris

    Not yet reported Khyber Teaching Hospital 92 participants Est. completion 2027-11-06 Stand-alone
    Other conditions: Pemphigus Vulgaris, Rituximab (RTx)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Rituximab, Rituxan Hycela, Truxima, Rituxan, Riabni, Ruxience

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.